The Interplay between Antimicrobial Stewardship and Resistance: A Global Perspective

Prabhat Jha, Sandip Kumar Tiwari, Rupali Bharti Sao*
Faculty of Pharmacy, Kalinga University, Raipur, Chhattisgarh, India
*Corresponding Author: Dr. Rupali Bharti Sao

Abstract:

Patient engagement review of antimicrobial stewardship programs on the status. An impending global public health threat, Antimicrobial resistance (AMR) is a critical public health, economic, and social concern globally. The first comprehensive report synthesizing data from national and international surveillance systems, to emphasize the breadth of antimicrobial resistance (AMR) around the world. The critique mentions antibacterial resistance (ABR), currently the biggest threat with its highly resistant nature in bacteria that create typical infections. AMR holds a serious global public health hazard, including spreading disease and causing death. In addition, AMR has immense economic burdens for healthcare providers. Multidrug-resistant (MDR) bacteremia can have implications on both clinical and economic outcomes as well. Excessive use of antimicrobial agents, responsible for antibiotic resistance, has been utilized in order to encourage resistant pathogens. The presence of resistant pathogens is partly driven by excessive use of antimicrobial agents in medicine, veterinary practice, and agriculture. Accelerated development of resistance mechanisms is driven by irresponsible use of antimicrobial agents in animal treatment, poultry, and pigs. AMR is therefore at the core of the global health system since it rapidly undermines the efficacy of antibiotics to treat mundane and trivial infections and is annihilating the foundations of modern medicine. In this article, we introduce the urgent call for a global cooperative effort to counteract AMR. The article also takes into consideration the innovative measures such as augmenting antimicrobial stewardship programs, proper use of antibiotics in the healthcare sector as well as in agriculture and creating new antibiotics. The LMICs, despite having such problems of lacking resources and low consumption rates, have a much higher percentage of antimicrobial resistance problems. The rising numbers of antibiotic-resistant microorganisms are posing an international health crisis. There are many genes for antibiotic resistance, and most of them can be simply transferred from one bacterial strain to another. New modes of transmission and new genes beyond those known emerge on a daily basis. Among the advantages of these enzymes, which are modifying antibiotics, is that they actively restrict the concentration of the drug in their natural environment. Thus, this is a highly acute issue for scientists and clinicians who are looking for new methods of anti-infective therapy. Antimicrobials are not typically modified by genetic mutations and are therefore typically modified by enzymatic processes.

The enzymatic processes that cause the modifications are typically readily transmissible from disease-causing pathogens to other disease pathogens. To treat resistant bacteria, we must understand how the enzymatic pathways facilitate these changes to occur.

Introduction:

Antibiotic Stewardship and Resistance

By promoting selection of the appropriate dosage regimen (dosage being variables considered), duration of treatment, and route of administration, this intervention is a choreographed attempt at optimizing and monitoring proper use of antimicrobial agents. Stewardship is an ethical expectation that portrays careful management and planning of scarce resources [1]. Analysis Antibiotic stewardship has come to be universally accepted as involving programs for responsible use of antibiotics so that they can continue to be effective for the public health. Antibiotic resistance increases the morbidity and mortality of patients, and harms public health. Physicians should exercise antibiotic stewardship and ought to prescribe antibiotics judiciously. Antibiotic treatment should be started early and reserved for individuals with unequivocal evidence of infection, or at least raise a reasonable doubt about the same [2].

Antibiotic Resistance

Antimicrobial drug resistance is where the antibiotic properties become too toxic to the microbe in order to initiate deaths, particularly such infections as pneumonia, diarrhea, gonorrhea, tuberculosis, HIV/AIDS, or malaria [3]. Abuse of antibiotics either because of their surplus, shortage, inappropriate use, or even drug abuse harms patients (since patients are given additional opportunities for treatment failure as well as adverse drug effects) as well as the whole medical field worldwide in passing resistant agents to more humans. AMR undermines the control of some common diseases, for example, pneumonia, diarrhea, gonorrhea, tuberculosis, HIV/AIDS, malaria, and more. Antibiotic resistance is on the rise in Gram-negative bacteria-even in our part of the world here in the United Kingdom- and new antibiotics are on the horizon [4]. There is a moral duty, part of which should fall to doctors — especially acute and general medical physicians — to comprehend, approve of, and advocate tenets of antibiotic stewardship. There are many genes coding for antibiotic resistance. In antibiotic resistance, some are transmissible from one bacterium to another. Along with the acquisition of new genes and mechanisms of transfer, new mechanisms of resistance to antibiotics are continuously discovered. This article announces recent progress in the understanding of bacterial antibiotic resistance, prevent mechanism to drug access to the target or acquired or intrinsic.

Global Burden and Data:

The actual impact of the resistance of bacteria to antibiotics on the world's health does not exist in the real world. Although efforts have been made to quantify the impacts of resistance to combinations of particular antibiotic-bacterial disease, some clinical syndromes, antibiotics, and healthcare systems (mainly in the developed world) [5], there is non-standard methods, measurements, and coverage. some of the importance of antimicrobial resistance are: raising awareness and behavior change related to wasteful use of resources AMS programs are intended to prevent wasteful antimicrobial use, one of the key reasons for resistance [6], Ensures that appropriate measures will be followed AMS programs guarantee antimicrobials will only be used when absolutely required and withdrawn by following right standards and documented best practices, etc.

Typical clinical scenarios in which antibiotic treatment reduces the risk of death include:

Category of Criteria	**Condition**
Diseases That Can Be Spread	Tuberculosis, sexually transmitted bacterial infections, respiratory bacterial infections (particularly those affecting the lower respiratory tract), bacterial diarrhea, and bacterial infections acquired in healthcare settings.
Infections that are endogenous	Urinary tract infections, skin and soft tissue infections, ineffective endocarditis, and sepsis.
Infection prevention	Burns, wounds, Caesarean sections, joint replacements, cancer treatment, and organ transplantation

As early as 2019, up to 5 million deaths were attributed to bacterial antimicrobial resistance (AMR), with approximately 1.27 million having died directly [7]. Estimates now are for over 39 million AMR attributable deaths from 2022 to 2050. Up to 80 percent of the AMR burden are associated with intra-abdominal infections, bloodstream infections, and lower respiratory infections. The most significant organisms that caused these deaths included Escherichia coli and Staphylococcus aureus. The case fatality rate was lowest in Australia and the highest in South Asia and Sub-Saharan Africa [8]. There has been a profound change in the mortality rates due to AMR between the periods 1990-2021, with more than a 50% decline among children aged below 5 years, compared to a rise of more than 80% among those aged over 70 years.

The key drivers of Antimicrobial Resistance (AMR) are Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, and the rest of the Pseudomonas aeruginosa and Acinetobacter baumannii [9]. AMR caused by these pathogens has increased to 930,000 deaths, where MRSA accounted for over 100,000 of these [10]. Not to include, 50 to 100 thousand deaths caused by six additional pathogen-drug pairs. As explained in the attached Box, to estimate PAF for death due to antibiotic resistance one would need to know the patients with resistant infection who died due to such infection. It also needs to take into account the targeted population of non-resistant infected patients but not dead. The extent of determining precisely the population targeted relies on having essential information about the incidence of the clinical condition, its aetiologies, and the coverage level of the desired antibiotic [11].

Gene Mutation & Horizontal gene transfer of antibiotic resistance.

Horizontal gene transfer enables genes to circumvent traditional vertical transmission via a number of mechanisms. As a single antibiotic resistance gene (ARG) can render many unrelated pathogens resistant, horizontal gene transfer (HGT) is an important cause of infectious disease. While antimicrobials that can cure or suppress infectious diseases efficiently are a precious resource in clinical practice, resistance is nevertheless developing, mutating, and disseminating rapidly [11]. At least 700,000 individuals die every year due to antibiotic-resistant infections globally, and within 30 years, such infections will claim 10 million lives yearly, many more than cancer kills. Hospitalization and routine interventions are becoming ever more dangerous due to the problem of bacterial antibiotic resistance (AR). This is particularly a problem in long-term acute care hospitals, where moreover 25% infections associated with healthcare are due to antibiotic-resistant bacteria. To fight the escalating problem of antimicrobial resistance (AR), it is necessary to learn how bacteria acquire and spread resistance genes in clinical settings [12].

Antibiotic resistance and Horizontal Gene Transfer (HGT)

It can be said that one of the chief reason of the development of antibiotic resistance is the misuse and overuse of antibiotics. The production of mutations in nucleic acids, which are the substrate for natural selection, is a fundamental component of evolution. As most bacteria have haploid genes and typically have short generation times, mutations should emerge and start to build up at an accelerating rate, causing measurable phenotypic changes that manifest almost instantaneously [13]. Hypermutator strains of Pseudomonas aeruginosa have also been isolated in the cystic fibrosis patient lungs in the clinic, but a prolonged role for hypermutator in the onset of clinically documented.

Enzymatic Degradation and Role of Efflux pumps for Antibiotic Resistance

Transport proteins called efflux pumps help in the extrusion of toxic substances from inside cells to the external environment, e.g., virtually all clinically beneficial antibiotics. The pumps can move a range of chemically distinct compounds, e.g., antibiotics of various classes, or could be substrate-specific. Efflux transporters are grouped under five big family categories: MFS(Major Facilitator) Superfamily, MATE(Multidrug and Toxic Efflux), RND(Resistance-Nodulation-Division),SMR(Small Multidrug Resistance)and ABC(ATP Binding Cassette Superfamily) [14] .



Several chemically unrelated compounds, like antibiotics of various drug classes, could be carried by more than one efflux pump, or they might be substrate specific. Pumps with multiple material transport activities are usually associated with multidrug resistance (MDR). Efflux pumps of clinical importance can render antibiotics employed in the treatment of bacterial infections less potent. Efflux pumps are all but universal among bacterial species as the genes for them are normally located on chromosomes or plasmids [15]. Modification group transfer reactions like modifications thiol transfer, ribosylation, nucleotidylation, glycosylation, phosphorylation, and acyl transfer are the most versatile. Hydrolysis is in particular truly stunning in the clinic—most noticeably with β-lactam antibiotics—but there are some enzymes which modify antibiotics by actually lowering the drug's levels within the surrounding environment. This is a significant challenge to scientists and clinicians in such instances as they attempt to discover new methods of anti-infective therapy.

<table>
<tr><th colspan="3">Multidrug Efflux Pumps</th></tr>
<tr><td rowspan="2">Endogenous Compounds
Siderophores

QS-related compound</td><td colspan="2">Exogenous Compounds
Antimicrobials</td></tr>
<tr><td>Antibiotics</td><td>Biocides</td></tr>
<tr><td></td><td colspan="2">Pollutants</td></tr>
<tr><td></td><td>Heavy metals</td><td>Solvents, xenobiotic</td></tr>
</table>

Toxic metabolites	InterKingdom interaction Bacteria-plant Gut

This evaluation will summarize recent understanding of such mechanisms of antibiotic resistance and the means by which a complete grasp of mechanisms, 3dimensional structure, and evolutionary history of resistance enzymes can be applied to combat resistance [16].

Biofilm formation in Antibiotic resistance

Two of the main concerns are the accumulation of germs on the surface and the resistance to current antibiotics. Several factors are responsible for the control and initiation of biofilm growth, including quorum sensing, unfavorable environmental conditions, availability of nutrients, hydrodynamic conditions, intercellular communication, signal transduction pathways, and secondary messengers. Microbial biofilms are acute threats to human, animal, and food industries through causing infections like antibiotic resistance, immune evasion, chronic infection, deaths associated with biofilm, and food spoilage. This is a recap of the biofilm formation, emphasizing its structure, composition, genes and pathways to its formation, and mechanisms of antibiotic resistance among microorganisms in biofilms [17].

Drivers of Antibiotic Resistance

Overuse & misuse in healthcare settings:

The cycle of overuse of antibiotics is only worsening the global health crisis of AMR, leading to more difficult-to-treat infections, extended hospitalization, and a higher number of fatalities. Antibiotics are being inappropriately prescribed for minor illnesses in primary care, even though most infections are viral. General practitioners themselves prescribe almost 90% of antibiotic prescriptions, and a vast majority of them are for respiratory infections that do not necessitate antibiotics. Overprescribing antibiotics can lead to more side effects and unnecessary treatments for mild conditions. This is particularly troubling in primary care, as most infections are viral in nature. General practitioners account for nearly 90% of antibiotic prescriptions, primarily for respiratory infections. Research indicates that combined efforts are more successful than individual actions in reducing antibiotic misuse [18].

Role of agriculture & veterinary use:

Not only in hospitals but also antibiotics are used in veterinary and agricultural medicine. And they are used very commonly in a way that it might be similar to those used in human medicine. Depending on different factors, like the health of the economy, the government's policy towards farming, farming systems, and the kind of animals being used, the choice and application of such antibiotics. This difference is caused by a number of determinants that may involve government policy, poor animal husbandry, and high infection levels [19]. These determinants include a common incidence or frequency of the infections, a high rate of a lack of governmental regulation and development programs, deficiencies in agricultural zoning, irrelevant sanitary practices in animal husbandry, and institutionalization of an integrated agricultural system. The power to prescribe antimicrobials rests with veterinarians, and care must be exercised that this prerogative is exercised judiciously. Because animal health and welfare depend upon judicious use of antibiotics varying from the selection of appropriate drugs to its dose as well as ensuring certain that the duration given by local authorities and offered test procedures. Antimicrobials should never be used where good practice of hygiene and management exists [20].

Lack of rapid diagnostics:

Fighting AMR is as complex as fighting global warming, and successful solutions require unity and coordination between various sectors like human health, animal health, fisheries and aquaculture, environmental management, food production, and agriculture, among others. Lack of timely and appropriate diagnostics plays a huge role in the issue of antibiotic resistance due to the fact that healthcare providers resort to administering antibiotics without knowing the cause of the disease or whether the disease can adapt to therapy. The Diagnostic to Address Antimicrobial Resistance report underscores that increasing point of care usage and availability particularly for point-of-care rapid testing is an imperative step against antimicrobial use and balancing the AMR conundrums. Instead, the emphasis is placed on rapid tests with center stage importance to healthcare as they conveniently detect specific infection-causing bacteria. This enables doctors to select the appropriate antibiotic and validate its effectiveness through susceptibility testing. Examples are point-of-care testing, molecular resistance organism diagnostics, and old-fashioned microscopy and culture, which may be slower but still yield useful information regarding bacteria and their antibiotic susceptibility [21].

Antibiotics: Their Role and Proper Use

Antimicrobial resistance (AMR) is developing into the biggest global economic and world health issue at breakneck pace. With more and more bacteria becoming resistant to our antibiotics, even common infections and small cuts and scrapes could once more prove deadly to us. Resisting AMR is not an easy problem to tackle—it is as intimidating as resisting climate change. Antibiotics account for a huge percentage of a hospital's pharmacy charges [22]. Therefore, the rational use of antibiotics is necessary to gain optimal patient benefits, to avert the emergence of antibiotic resistance, and to minimize healthcare costs.To make this a reality, the report advises four significant actions:

1. Enhance financial investment in the production and distribution of diagnostic products, particularly in lower-income countries where access is most restricted.

2. Leverage the experience from COVID-19, i.e., widespread use of rapid tests, to normalize the use of diagnostics in routine healthcare.

3. Support healthcare professionals through the integration of diagnostics into daily practice and educating professionals about how and when they should apply these tests.

4. Establish patient and professional awareness of the dangers of excessive use of antibiotics and the promise of diagnostics to prevent.

Antibiotic Stewardship Programs aim for rational prescribing practices.

This program brings together different sectors to ensure antibiotics and other antimicrobial medications are used wisely and effectively. The goal is to help healthcare providers choose the right drug, give it in the right dose, for the right amount of time, and by the most effective route—oral or intravenous [23]. National government health departments, global organizations, and pharmaceutical companies all have their parts to play in keeping antimicrobial use on track. They are even more successful when combined with strong infection prevention and control measures.

Objective:

The primary objectives of antibiotic stewardship are to: Ensure patients with bacterial infections receive appropriate treatment and too cut wasteful prescriptions and limit collateral damage.

Antibiotic Stewardship Programs (ASPs) – Strategies & Implementation

Antibiotic Stewardship Programs (ASPs) are the highest priority of antibiotic use management across the healthcare setting. As crucial as the programs are to quality prescribing and avoiding the emergence of antibiotic resistance, however, implementation was not perfect. The CDC suggests the necessity of ASPs against antibiotic resistance, especially in ICUs and hospitals. With programs implemented, there are the appropriate antibiotics prescribed, improving therapy while decreasing instances of adverse effects like CDIs. Systematic stewardship interventions can allow clinicians to balance effective therapy with proper use of antibiotics—healthy for both patients and public health in the long run. Antibiotic stewardship is applied in various areas, including: Antibiotic Stewardship in Pediatrics, Antibiotic Stewardship Programs in Hospitals, Antibiotic Stewardship in the I.C.U. and Antibiotic Stewardship in Nursing Homes [24].

LEADERSHIP COMMITMENT, ACCOUNTABILITY, AND DRUG EXPERTISE

Having a physician, typically, program leader ensures accountability and proper communication of requirements and outcomes to an executive-level or quality-focused committee. In addition, having pharmacists with their necessary pharmacological know-how is essential. They may be leaders or advisors to ensure the program will most probably provide accurate and effective suggestions. Antibiotic stewardship and direct education in infectious disease enhance the ability of the leadership team to remain up to date with current practice. Full-time staff can be hired within large companies to manage stewardship programs, or smaller hospitals can utilize hospitalists, part-time professionals, or off-site consultants [25]. Through gaining management endorsement, economic support, seasoned management, and comprehensive training, healthcare institutions can create effective stewardship programs that provide improved patient care, prevent antibiotic resistance, and reduce healthcare costs.

ACTIONS TO IMPROVE ANTIBIOTIC PRESCRIBING

To support antibiotic prescribing protocols, there ought to be organizational policies and procedures that are appropriate for managing antibiotic use and specific disease. The policies should include procedures for administering antibiotics in timely manner in vital cases like serious infections. The policies must give accurate documentation of dosage and duration for every prescription. Policies should, however, be complemented by interventions targeting specific interventions according to the facilities' resources. Coordination between health staff and monitoring prescribers' guideline compliance are in order. Patient-focused reviews can help identify success and areas to improve. Hospital Antibiotic Stewardship Programs (ASPs) must monitor overall-hospital use of antibiotics, with emphasis on trends and rates of resistance to inform practice. Case reviews with clinicians can optimize treatment for various patient care scenarios. Internet-based educational materials can aid ongoing improvement in prescribing practice [26].

In intensive care units (ICUs), the rise in antimicrobial-resistant microbes due to exponential increase is a global emergency that occurs mainly due to excessive use of antibiotics. Timely diagnosis and adequate treatment of infections, optimal dosing, and not using unnecessary broad-spectrum antibiotics constitute good stewardship. Delayed treatment can gravely increase the risk of death, and thus guidelines recommend that sampling should never delay early administration of antibiotics, particularly in septic patients. Balancing immediate treatment and achieving proper diagnosis are essential. Empirical broad-spectrum antibiotics are often needed due to increasing bacterial resistance. Regular reviews must be maintained to avoid overprescribing. Treatment courses must be shortened in duration to overcome resistance, and most infections can be successfully treated within a week if the patient responds favorably to initial therapy [27]. Successful development of formalized stewardship programs that combine multiple interventions is essential to succeed. In pediatrics, antibiotics have profound unintended consequences, including resistance and infections such as Clostridioides difficile. ASPs function to ensure that antibiotics are only prescribed when absolutely necessary. Their use is supported by leading health agencies, emphasizing the significance of evidence-based policies in inpatient and outpatient environments.

Effective stewardship depends on direct communication, pre-authorization of some antibiotics, and post-prescription review, all founded on local and evidence-based guidelines. Rapid diagnostic tests can greatly contribute to maximizing antibiotic use, through rapid de-escalation or cessation of therapy on the basis of valid results, but costs and logistics remain obstacles. Overall, interprofessional dialogue and continuous education are necessary to maximize prescribing and fight resistance. Antibiotic overuse in children in the U. S. is a high priority, with as many as 50 million prescriptions being written annually, most of them unnecessary, particularly for respiratory infections. It is a cause of the spread of antibiotic resistance and side effects. In pediatrics, good stewardship of antibiotics is required to reduce these issues, which can be achieved by increased diagnostic testing, clinical guidelines, and educational opportunities for healthcare providers [28].

In outpatient practice, antibiotic stewardship differs from inpatient antibiotic stewardship. In EDs, antibiotic stewardship has a key role to play in optimizing antibiotic prescribing, where instant prescribing decisions need to be taken. Clinical guidelines and technology implementation can enhance appropriate prescribing. It is crucial to decide when antibiotics are unnecessary, especially in common conditions like bronchitis and conjunctivitis, which can decrease antibiotic use by 30%. Diagnostic stewardship can also avoid inapt prescribing, for example, by confirming infections before they are treated with antibiotics.

Even where antibiotics are appropriate, the right ones must be prescribed. Far too often, broad-spectrum antibiotics are given unnecessarily instead of narrow-spectrum agents, with consequent unnecessary expense and resistance with no further clinical benefit [29]. Many simple infections also might be managed with shortened courses of antibiotics as opposed to the standard recommended duration. Outpatient antibiotic stewardship is hindered by recruiting outpatient physicians and by sustaining long-term momentum. Inside the long-term care facility, antibiotic stewardship takes on a greater sense of urgency due to growing antibiotic resistance and the vulnerable aging population inside. A not unusual issue of repeated antibiotic use in nursing home patients makes stern stewardship essential in order to properly use them. Unique challenges present in facilities there are, however--e.g., infection diagnosis challenges and legacy lab tests causing delays in results.

Overall, responsible antibiotic use is key in outpatient and long-term care to protect the public's health and combat resistance crises. One Health places prioritization of reciprocally supporting human, animal, and environmental health in place to promote rational use of antibiotics.

Discussion

Antibiotic resistance is a significant global issue that must be more aggressively addressed in healthcare institutions. While initial antibiotic optimization reduces overprescribing, greater emphasis on activity after ordering, including review and adjustment of treatment, must occur. Nursing homes must also be assisted despite the lack of resources. Long-term effects of stewardship programs on costs, infection, and C. difficile rates must be addressed in future research.

Stewardship programmes are 20 years in the hospitals, but social barriers and resource paucity undermine their success. Prescribing practice variability by specialty tells us that part of stewardship intervention is essential.

Prohibition of over-the-counter antibiotic sales is required to prevent their inappropriate use, as self-treatment promotes resistance. Dispensing antibiotics only on prescription ensures that antibiotics are used appropriately and appropriately diagnosed.

Modern diagnostic technology is able to diagnose infection quickly, reduce inappropriate use of antibiotics, and enable judicious prescribing. Vaccines will also help by preventing infections requiring antibiotics and preventing transmission of resistance.

Antibiotic resistance increases the cost and length of care, extends hospital stays, and threatens essential medical interventions. Therefore, people need to be educated on the proper use of antibiotics to prevent misuse. Effective physician-patient communication can facilitate appropriate use.

The use of information technology in clinical practice can improve patient care through improved access to information and decision-making regarding the use of antibiotics. There needs to be studies on best practices for using antibiotics in hospitals and long-term healthcare facilities. There has been a move toward the development of new targeted antibiotics that have been found to reduce resistance when used at the start of treatment. Collaboration between sectors among healthcare providers, drug developers, and policymakers is the key to success in reducing infectious diseases.

Conclusions

The commonly utilized "spiraling empirical" approach of giving preemptive broad-spectrum antibiotics in ICUs is likely to result in overuse by uninfected patients. It is not only creating more unnecessary healthcare costs, but also results in more widespread dissemination of resistant pathogens causing more virulent disease and rising mortality. Reining in antimicrobial resistance (AMR) requires international cooperation, focused on powering innovation in diagnostics, assured finance, and collaborative One Health approaches linking science, policy, and practice. Priorities must be tackled to facilitate the world community to ensure the use of antibiotics to function optimally in generations to come. In the USA, hospitals are instituting Antibiotic Stewardship Programs (ASPs) supporting antibiotic use with formal yet adaptable strategies.. These are supplemented by tools from the Get Smart for Healthcare program to assist institutions in implementing and enhancing stewardship programs. Successful stewardship is dependent upon an approach that encompasses a systems strategy of ongoing education of providers, process assessment on an organized basis, and feedback in a timely manner—all being critical components of changing prescribing practices and enhancing patient outcomes.

Reference:

1. Hanmant A, Priyadarshini K. Prescription analysis to evaluate rational use of antimicrobials. Int J Pharm Biol Sci. 2011;2(2):314-9.
2. Mangione-Smith R, Elliott MN, McDonald L, McGlynn EA. An observational study of antibiotic prescribing behavior and the Hawthorne effect. Health Serv Res. 2002;37(6):1603-23. doi: 10.1111/1475-6773.10482, PMID 12546288.
3. Emmerson M. Antibiotic usage and prescribing policies in the intensive care unit. Intensive Care Med. 2000;26(1);Suppl 1:S26-30. doi: 10.1007/ s001340051115, PMID 10786955.
4. Hogerzeil HV. Promoting rational prescribing: An international perspective. Br J Clin Pharmacol. 1995;39(1):1-6. doi: 10.1111/j.1365-2125.1995.tb04402.x, PMID 7756093.
5. World Health Organization. Combat antimicrobial resistance. Available from: http://www.who.int/world-health-day/2011/en/index.html. Accessed January 1, 2012.
6. Gould I. Controversies in infection: infection control or antibiotic stew ardship to control healthcare-acquired infection? J Hosp Infect 2009;73: 386-91.
7. Hersh A, Beekman S, Polgreen P, Zaoutis T, Newland J. Antimicrobial stew ardship programs in Pediatrics. Infect Control Hosp Epidemiol 2009;30: 1211-7.
8. Craig W, Uman J, Shaw W, et al. Hospital use of antimicrobial drugs: survey at 19 hospitals and results of antimicrobial control program. Ann Intern Med 1978;89:793-5.
9. Hecker M, Aron D, Patel N, et al. Unnecessary use of antimicrobials in hospi talized patients. Arch Intern Med 2003;163:972-8.
10. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance; World Health Organization: Geneva, Switzerland, 2014. [**Google Scholar**]
11. Department of Health. English Surveillance Program Antimicrobial Utilization and Resistance (ESPAUR) Report; Department of Health: London, UK, 2014.
12. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe; European Centre for Disease Prevention and Control: London, UK, 2013. [**Google Scholar**]
13. Dellit, T.; Owens, R.; McGowan, J.; Gerding, D.; Weinstein, R.; Burke, J.; Huskin, W.; Paterson, D.; Fishman, N.; Carpenter, C.; et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiologyof America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. **2007**, 44, 159–177. [**Google Scholar**]
14. Tamma, P.D.; Holmes, A.; Ashley, E. Antimicrobial stewardship: Another focus for patient safety? Curr. Opin. Infect. Dis. **2014**, 27, 348–355. [**Google Scholar**] [**CrossRef**] [**PubMed**]

15. Goossens, H.; French, M.; vander Stichele, R.; Elseviers, M.; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet **2005**, 365, 579–587. [**Google Scholar**] [**CrossRef**]

16. Aldeyab, M.; Harbarth, S.; Vernaz, N.; Kearney, M.; Scott, M.; Darwish Elhajji, F.; Aldiab, M.; McElnay, J. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br. J. Clin. Pharmacol. **2012**, 74, 171–179.

17. Livermore, D.; Hope, R.; Reynolds, R.; Blackburn, R.; Johnson, A.; Woodford, N. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: Links to prescribing change? J. Antimicrob. Chemother. **2013**, 68, 2667–2674. [

18. Doron, S.; Davidson, L.E. Antimicrobial stewardship. Mayo Clin. Proc. **2011**, 86, 1113–1123. [**Google Scholar**] [**CrossRef**] [**PubMed**]

19. Owens, R., Jr. Antimicrobial stewardship: Concepts and strategies in the 21st century. Diagn. Microbiol. Infect. Dis. **2008**, 61, 110–128. [**Google Scholar**] [**CrossRef**] [**PubMed**]

20. Davey, P.; Brown, E.; Charani, E.; Fenelon, L.; Gould, I.; Holmes, A.; Ramsay, C.; Wiffen, P.; Wilcox, M. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst. Rev. **2013**, CD003543. [**Google Scholar**] [**CrossRef**]

21. Public Health England. Antimicrobial Stewardship: “Start Smart-Then Focus”; Public Health England: London, UK, 2015.

22. National Institute for Health and Care Excellence. Antimicrobial Stewardship:Systems and Processes for Effective Antimicrobial Medicine Use; National Institute for Health and Care Excellence: London, UK, 2015.

23. Australian Commission on Safety and Quality in Health Care. Antimicrobial Stewardship in Australian Hospitals; Duguid, M., Cruickshank, M., Eds.; Australian Commission on Safety and Quality in health Care: Sydney, Australia, 2011.

24. Patel, D.; Lawson, W.; Guglielmo, B.J. Antimicrobial stewardship programs: Interventions and associated outcomes. Exp. Rev. Anti-infect. Ther. **2008**, 6, 209–222. [**Google Scholar**] [**CrossRef**] [**PubMed**]

25. Nathwani, D.; Gray, K.; Borland, H. Quality indicators for antibiotic control program. J. Hosp. Infect. **2002**, 50, 165–169. [**Google Scholar**] [**CrossRef**] [**PubMed**]

26. Chen, A.; Khumra, S.; Eaton, V.; Kong, D. Snapshot of barriers to and indicators for antimicrobial stewardship in australian hospitals. J. Pharm. Pract. Res. **2011**, 41, 37–41. [**Google Scholar**] [**CrossRef**]

27. Morris, A.; Brener, S.; Dresser, L.; Daneman, N.; Dellit, T.; Edina, A.; Chaim, B. Use of a structured panel process to define quality metrics for antimicrobial stewardship programs. Infect. Control Hosp. Epidemiol. **2012**, 33, 500–506. [**Google Scholar**] [**CrossRef**] [**PubMed**]

28. Bumpass, J.; McDaneld, P.; DePestel, D. Outcomes and Metrics for Antimicrobial Stewardship: Survey of Physicians and Pharmacists. Clin. Infect. Dis. **2014**, 59, S108–S111. [**Google Scholar**] [**CrossRef**] [**PubMed**]

29. Almirante, B.; Garnacho-Montero, J.; Pachón, J.; Pascual, Á.; Rodríguez-Baño, J. Scientific evidence and research in antimicrobial stewardship. Enferm. Infecc. Microbiol. Clin. **2013**, 31, 56–61. [**Google Scholar**] [**CrossRef**]